3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
4
OTHER
3
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
19
Lymphoma
3
Neoplasms, Plasma Cell
2
Smoldering Multiple Myeloma
1
Sezary Syndrome
1
Myelodysplastic Syndromes
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Specimen Handling
2
Methods
2
Educational Status
2
Early Intervention, Educational
2
trihexyltetradecylphosphonium chloride
1
letermovir
1
gamma-Globulins
1
Voriconazole
1
Vincristine
1
Vaccination
1
Sirolimus
1
Prednisone
1
Pharmacogenomic Testing
1
Patient Navigation
1
Organizational Objectives
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone Acetate
1
Methylprednisolone
1
Lenalidomide
1
Interviews as Topic
1
Infliximab
1
Immunoglobulins, Intravenous
1
Immunoglobulins
1
Health Promotion
1
Fluconazole
1
Cyclophosphamide
1
Cord Blood Stem Cell Transplantation
1
Caspofungin
1
Carvedilol
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Hematologic Neoplasms
×
Lenalidomide
×
Clear all
NCT01460420
2017-07-06
EMN-alloRIC
European Myeloma Network B.V.
Phase 1/2
Completed
49 enrolled